The present invention discloses new medical uses of phosphodiesterase 4 (PDE 4) inhibitors for treating dyslipoproteinaemia and of diseases when respectively correlated or associated with dyslipoproteinaemia or lipoprotein imbalance, in particular abnormally high low density lipoprotein (LDL) in blood or serum, such as endothelial dysfunction, cardiovascular diseases, in particular arteriosclerosis, myocardial infarction, stroke, peripheral artery disease, and vascular stenosis or restenosis, independent and distinct from inflammatory diseases or conditions such as inflammatory-associated cardiovascular pathology and cardiac hypertrophy. Accordingly the present invention allows reducing cardiovascular risks in new clinical settings, especially in circumstances of abnormal high LDL levels and especially LDL-cholesterol and LDL-triglyceride levels.
